U.S. markets closed

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
145.24+0.16 (+0.11%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close145.08
Open145.88
Bid145.30 x 900
Ask145.69 x 800
Day's Range144.35 - 147.47
52 Week Range109.16 - 157.00
Volume3,909,053
Avg. Volume5,944,217
Market Cap382.391B
Beta (5Y Monthly)0.69
PE Ratio (TTM)22.84
EPS (TTM)6.36
Earnings DateOct 13, 2020
Forward Dividend & Yield4.04 (2.78%)
Ex-Dividend DateAug 24, 2020
1y Target Est166.18
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-12% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Motley Fool

    What Are the Differences Between the Leading Coronavirus Vaccine Candidates?

    All of the leading coronavirus vaccine candidates share one quality: They seek to spur the body's immune system to fight future infections of the virus that causes COVID-19. In this Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Keith Speights discuss the main differences between the leading coronavirus vaccines in development. Corinne Cardina: So let's get into the stocks.

  • Motley Fool

    3 Coronavirus Vaccine Stocks That Especially Stand Out Right Now

    More than 40 coronavirus vaccine candidates are currently in development, according to the World Health Organization. In this Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Keith Speights discuss three coronavirus vaccine makers that stand out right now. Corinne Cardina: Diving into some of these specific stocks a little bit more.

  • American Express Hit With 40% Profit Slump; Shares Fall 3.6%
    SmarterAnalyst

    American Express Hit With 40% Profit Slump; Shares Fall 3.6%

    Shares in American Express depreciated 3.6% on Friday after the credit card issuer posted a 40% decline in quarterly profit and forecast that business travel is not going to recover until late 2021 or early 2022.AmEx’s (AXP) third-quarter profit plunged 40% to $1.07 billion, or $1.30 per share from the same period last year, falling short of analysts’ expectations of $1.35 per share. Total revenues, net of interest expense, dropped 20% to $8.8 billion year-on-year, primarily due to lower Card Member spending.Overall spending on AmEx cards was down 19% at $248.7 billion during the reported quarter. Travel and entertainment (T&E) related spending dived 69% year-on-year, while non-T&E-related spending was up 1% during the same period. Online consumer retail spending was up 32% over last year.Consolidated provisions for credit losses amounted to $665 million, down 24% from $879 million a year ago.“While our business continues to be significantly affected by the impacts of the pandemic, our third quarter results have increased our confidence that our strategy for managing through the current environment is the right one,” said AmEx CEO Stephen J. Squeri. “Since the lows of mid-April, we have seen a steady recovery in our overall spending volumes. In fact, we had positive year-over-year growth in non-T&E spending, which has long accounted for the large majority of our overall volumes.”“While credit remains strong, with delinquencies and net write-offs at the lowest levels we have seen in a few years, we remain cautious about the direction of the pandemic and its impacts on the economy, which is reflected in our reserve levels,” Squeri added.Squeri said he expects to see a tick-up in consumer behavior from a travel perspective toward the end of the year, or first quarter of next year. In terms of business travel, the CEO projects a recovery not until late 2021 or early 2022.AmEx shares have dropped 19% this year as the credit card issuer’s revenue was hurt by a sharp drop in T&E spending due to the stringent COVID-19 restrictions. Looking ahead, the $105.50 average analyst price target implies 4.5% upside potential over the coming year.Earlier this month, Susquehanna analyst James Friedman downgraded the stock to Hold from Buy with a $110 price target, as a recovery in spending to pre-pandemic levels looks far away.“It would be hard for AXP to do better than their merchants, so consensus ‘21 revenue up 11% looks full to us,” Friedman wrote in a note to investors. He said growth of 7.5% appears more reasonable after looking at projections for the airline, hotel, dining, and retail industries.Overall, Wall Street analysts are sidelined on the stock. The Hold consensus breaks down into 5 recent Hold ratings, 4 Sell ratings versus 3 Buy ratings (See AXP stock analysis on TipRanks).Related News: Mattel Jumps 6% As 3Q Earnings Crush Expectations Chipotle Falls 4% As Delivery Costs Drag Down 3Q Earnings Intel Sinks 9% As 3Q Data-Center Sales Disappoint More recent articles from Smarter Analyst: * Coca-Cola European Partners In Talks To Buy Australian Bottler – Report * AutoZone vs Advance Auto: Which Retail Stock Is A Better Pick? * RBC Turns Bullish On PulteGroup, Sees 21% Upside * AstraZeneca Gets FDA Nod To Resume US Covid-19 Trial